Drug regulator issues alert about cyber security risk in Medtronic insulin pumps

Says some models are vulnerable to hackers, who can change settings wirelessly

July 04, 2019 02:57 pm | Updated 05:00 pm IST - NEW DELHI:

India has a growing population of diabetics. File

India has a growing population of diabetics. File

A week after the U.S. Food and Drug Administration (FDA) warned about cybersecurity risks attached to some models of insulin pumps manufactured by American medical equipment supplier Medtronic, India’s apex drug regulator, the Central Drug Standard Control Organisation (CDSCO) has also issued an alert.

CDSCO noted that some models were vulnerable to hackers and an unauthorised person with technical skills and equipment could potentially connect wirelessly to a nearby insulin pump to change the settings and control insulin delivery. India has a growing population of diabetics. 

CDSCO has advised that patients and caregivers should check and see if the model and software version of their insulin pump is affected, talk to their healthcare provider about a prescription to switch to a model with better cyber security protection, keep the insulin pump and the devices that are connected to them within their control and not share their pump serial number and be attentive to pump notifications, alarms and alerts.

It further advises patients to disconnect the USB device from their computer when it is not being used to download data from their pump.

The affected models include Minimed Paradigm (MMT-715, MMT-712 & MMT-722) and MiniMed Paradigm Veo (MMT-754) Insulin Pump.

Company’s response

Responding to the alert, an official statement on behalf of Medtronic India said: “On June 25, 2019, Medtronic notified customers of potential cybersecurity risk in the MiniMed508 and MiniMed Paradigm series of insulin pumps; these models are from 2012 and earlier…” 

“At this time, we have not received any confirmed reports of unauthorised persons changing settings or controlling insulin delivery. Medtronic provided its customers and their doctors with recommended security precautions when using their insulin pump. This is a safety notification only.’’

It said that in India, Medtronic was pro-actively informing the regulators and other relevant stakeholders and was in the process of working with researchers, doctors and patients to address any questions or concerns that they may have.

“No patient issues have been reported in India so far. MiniMed 508 had been discontinued in India since 2011,” it added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.